Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR2E3 | Q9Y5X4 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460878 | 0.91 | RAB9A (0.57) | RAB9ANPC1DGAT1LMNAMAPT | |
| SCHEMBL4481398 | 0.81 | MT-CO2 (0.50) | RAB9ANPC1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2979954 | 0.81 | MAPT (0.44) | RAB9ANPC1CYP1A2DGAT1ATR | |
| SCHEMBL4477969 | 0.81 | NR2E3 (0.55) | RAB9ANPC1MAPTNR2E3 | |
| SCHEMBL4472721 | 0.81 | NR2E3 (0.59) | NR2E3 | |
| SCHEMBL1136446 | 0.79 | KMT2A (0.50) | RAB9ANPC1CYP1A2PPARGDGAT1 | |
| SCHEMBL4473673 | 0.77 | NR2E3 (0.54) | MAPTNR2E3 | |
| SCHEMBL4479479 | 0.76 | NR2E3 (0.53) | RAB9ANPC1MAPTSMN1; SMN2NR2E3 | |
| SCHEMBL4483144 | 0.76 | NR2E3 (0.52) | RAB9ACYP1A2PPARGLMNAMAPT | |
| SCHEMBL4473723 | 0.76 | KMT2A (0.57) | MAPTSMN1; SMN2NR2E3MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618964-B2 | Benzamide derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-14 | — | — | US | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-7618964-B2 | Benzamide derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-14 | — | — | US | disclosed |
| EP-1833829-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006066913-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | RAB9A 4675/4885NPC1 4189/4885CYP1A2 4534/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | RAB9A 4685/4885NPC1 4268/4885CYP1A2 4656/4885 |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | TMBIM6, BAK1, CYP3A5 | RAB9A 1396/4885NPC1 847/4885CYP1A2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.